Drug
Pyrotinib
Pyrotinib: highest development phase Phase 2, developed by Jiangsu Hengrui Medicine. 3 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Jiangsu Hengrui Medicine
Trials
| Drug | Phase | Indication |
|---|---|---|
| Pyrotinib NCT04398914 | Phase 2 | Breast Cancer Invasive |
| Pyrotinib NCT03997539 | Phase 2 | Metastatic Breast Cancer |
| Pyrotinib Maleate NCT04680091 | Phase 1 | Healthy Subjects, Drug-drug Interaction, Pyrotinib |
Latest
No recent events.
Follow Pyrotinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.